Definium Therapeutics, Inc. (DFTX)
44.81
+1.54
(+3.56%)
USD |
NASDAQ |
Aug 25, 16:00
44.67
-0.14
(-0.31%)
After-Hours: 04:06
Definium Therapeutics EPS Diluted (Quarterly) : -1.436 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.436 |
| March 31, 2026 | -0.7087 |
| December 31, 2025 | -0.5106 |
| September 30, 2025 | -0.7832 |
| June 30, 2025 | -0.5008 |
| March 31, 2025 | -0.2745 |
| December 31, 2024 | -0.4139 |
| September 30, 2024 | -0.2747 |
| June 30, 2024 | -0.0814 |
| March 31, 2024 | -1.137 |
| December 31, 2023 | -0.5924 |
| September 30, 2023 | -0.4512 |
| June 30, 2023 | -0.7551 |
| March 31, 2023 | -0.6517 |
| December 31, 2022 | -0.1291 |
| September 30, 2022 | -0.5627 |
| June 30, 2022 | -0.6004 |
| March 31, 2022 | -0.6555 |
| December 31, 2021 | -0.6664 |
| September 30, 2021 | -9.208 |
| June 30, 2021 | -1.652 |
| March 31, 2021 | -0.5722 |
| December 31, 2020 | -0.6805 |
| Date | Value |
|---|---|
| September 30, 2020 | -0.463 |
| June 30, 2020 | -0.379 |
| March 31, 2020 | -0.5323 |
| August 31, 2019 | -1.617 |
| May 31, 2019 | -0.4127 |
| February 28, 2019 | -0.4722 |
| November 30, 2018 | -0.3586 |
| August 31, 2018 | -0.6175 |
| May 31, 2018 | -0.7489 |
| February 28, 2018 | -0.9532 |
| November 30, 2017 | -0.9557 |
| August 31, 2017 | -1.864 |
| May 31, 2017 | -1.781 |
| February 28, 2017 | -0.9082 |
| November 30, 2016 | -1.810 |
| August 31, 2016 | 0.00 |
| May 31, 2016 | 0.00 |
| February 29, 2016 | 0.00 |
| November 30, 2015 | 0.00 |
| August 31, 2015 | 0.00 |
| May 31, 2015 | 0.00 |
| February 28, 2015 | 0.00 |
| November 30, 2014 | 0.00 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Cocrystal Pharma, Inc. | -0.2295 |
| CNBX Pharmaceuticals, Inc. | -0.0001 |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | 2.578 |
| Fulcrum Therapeutics, Inc. | -0.3433 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -158.99M |
| Total Expenses (Quarterly) | 158.99M |
| Enterprise Value | 4.974B |
| Earnings Yield | -7.67% |
| Normalized Earnings Yield | -5.679 |